Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.

J, Sieper; R, Landewé; M, Rudwaleit; der Heijde D, van; M, Dougados; PJ, Mease; J, Braun; A, Deodhar; A, Kivitz; J, Walsh; B, Hoepken; T, Nurminen; WP, Maksymowych

doi:10.1002/art.38973

Public

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.

Shared by NobleBlocks on Mar 1, 2015 • 12:00 AM UTC

Authors:

Sieper J

Landewé R

Rudwaleit M

Abstract

<h4>Objective</h4>Previous reports of the RAPID-axSpA trial (NCT01087762) described the efficacy and safety of certolizumab pegol (CZP) over 24 weeks in patients with axial spondyloarthritis (SpA), including ankylosing spondylitis (AS) and nonradiographic axial SpA. We report efficacy and safety dat...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!